Tag Archives: Pneumonia
Why does our local CAP guideline differ from Australian Therapeutic Guidelines?
Kristi, Lorrae and Ayesha have recently joined as AIMED authors– welcome aboard. Here’s a posting from Kristi that unpacks the approach to community-acquired pneumonia (CAP) in Hunter New England Health, NSW. In adults, the most common bacterial cause of community-acquired pneumonia (CAP) is Streptococcus pneumoniae. Other pathogens associated with CAP include Haemophilus influenzae and atypical’ […]
Do we need to cover ‘atypical’ community acquired pneumonia?
Guest posting: Dr John Burston, Staff Specialist, Infectious Diseases, Calvary Mater Hospital, Newcastle. Most antibiotic guidelines1-3 , including the HNELHD Community Acquired Pneumonia (CAP) guideline, suggest empirically treating community acquired pneumonia (CAP) with a macrolide or tetracycline to cover ‘atypical’ organisms. But is this necessary and what should be our approach? Beta-lactam monotherapy was non-inferior […]
Childhood pneumonia and its prevention (World pneumonia day yesterday!)
Learn about Pneumonia: Facts, Figures and What You Can Do [link fixed] Pneumonia Innovation Summit proceedings 2015 Preventing Pneumonia – CDC resource (USA): in the USA, pcv-13 vaccine is used initially to optimise the immunogenicity of subsequent 23-valent polysaccharide vaccine dose (Australia does not currently recommend this approach – repeat doses, 5 years apart to a maximum of […]
Community Acquired Pneumonia – updated HNELHD Guideline
The updated Hunter New England guideline, Adult Community Acquired Pneumonia: Initial Investigation and Empiric Antibiotic Therapy has now been released. Community acquired pneumonia (CAP) is a common cause of hospital admission, carrying a significant risk of morbidity and mortality. Approximately 1/3 of patients require admission to hospital. Streptococcus pneumoniae remains the commonest pathogen ( see here for […]
Tazocin misconceptions: misuse in community-acquired pneumonia – spectrum too broad
Piperacillin+tazobactam (Tazocin) is an important broad spectrum antibiotic that is still active in most Australian settings against a wide range of Gram negatives (including Pseudomonas) , Gram positives (excluding MRSA and VRE) and nearly all anaerobic bacteria. It comes into great demand for management of a range of healthcare-associated infections, especially in ICU. Its use […]
AIMED - Let's talk about antibiotics 